Jamie Cesanek | Authors


KRd-ASCT Improves Long-Term PFS in Multiple Myeloma

October 03, 2021

Promising survival results were shown in the FORTE trial of carfilzomib plus lenalidomide, and dexamethasone induction/consolidation with autologous stem cell transplant and maintenance with carfilzomib-lenalidomide in patients with multiple myeloma.

Greater Tolerability Is Seen With Iberdomide in Multiple Myeloma

October 03, 2021

Results from CC-220-MM-001 trial support further research of iberdomide-based regimens in multiple myeloma that investigators hope will lead to phase 3 randomized trials and eventual FDA approval of iberdomide in these combinations.

In De-Novo mCSPC, The Addition of Prednisone to Standard of Care May Be Practice-Changing

September 19, 2021

For the treatment of de novo metastatic castration-sensitive prostate cancer improved radiographic progression-free survival and overall survival was seen with the addition of prednisone to androgen-deprivation therapy plus docetaxel.

CAR T-Cell Therapy Prophylaxis With Anakinra May Reduce CRS and Toxicities in Multiple Myeloma

June 17, 2021

The frequency of moderate to severe cytokine release syndrome was reduced in patients with relapsed or refractory multiple myeloma who received anakinra prophylaxis with orvacabtagene autoleucel, a BCMA-targeted CAR T-cell therapy, according to findings presented at the European Hematology Association 2021 Virtual Congress.

Long-Term Survival Benefit with Durvalumab in NSCLC Confirmed in Updated Findings

June 04, 2021

Sustained overall survival and progression-free survival benefits was confirmed following long-term treatment with durvalumab following chemoradation in patients with unresectable stage 3 non-small cell lung cancer whose disease had not progressed after platinum-based concurrent chemoradiotherapy.